NSEI:CIPLA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India.


Snowflake Analysis

Excellent balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Cipla's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CIPLA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.3%

CIPLA

2.4%

IN Pharmaceuticals

7.4%

IN Market


1 Year Return

14.0%

CIPLA

18.1%

IN Pharmaceuticals

-17.6%

IN Market

Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 18.5% over the past year.

Return vs Market: CIPLA exceeded the Indian Market which returned -18.2% over the past year.


Shareholder returns

CIPLAIndustryMarket
7 Day1.3%2.4%7.4%
30 Day4.8%1.7%6.7%
90 Day45.5%13.3%-11.1%
1 Year15.8%14.0%20.0%18.1%-16.0%-17.6%
3 Year21.7%18.7%6.4%3.3%-5.4%-10.4%
5 Year11.6%8.2%-1.3%-5.0%19.3%8.0%

Price Volatility Vs. Market

How volatile is Cipla's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cipla undervalued compared to its fair value and its price relative to the market?

33.41x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CIPLA (₹641.2) is trading above our estimate of fair value (₹395.23)

Significantly Below Fair Value: CIPLA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CIPLA is poor value based on its PE Ratio (33.4x) compared to the Pharmaceuticals industry average (16.7x).

PE vs Market: CIPLA is poor value based on its PE Ratio (33.4x) compared to the Indian market (10.2x).


Price to Earnings Growth Ratio

PEG Ratio: CIPLA is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: CIPLA is overvalued based on its PB Ratio (3.3x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Cipla forecast to perform in the next 1 to 3 years based on estimates from 28 analysts?

17.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CIPLA's forecast earnings growth (17.6% per year) is above the savings rate (7.2%).

Earnings vs Market: CIPLA's earnings (17.6% per year) are forecast to grow faster than the Indian market (16.5% per year).

High Growth Earnings: CIPLA's earnings are forecast to grow, but not significantly.

Revenue vs Market: CIPLA's revenue (7.9% per year) is forecast to grow faster than the Indian market (7.2% per year).

High Growth Revenue: CIPLA's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CIPLA's Return on Equity is forecast to be low in 3 years time (12.2%).


Next Steps

Past Performance

How has Cipla performed over the past 5 years?

3.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CIPLA has high quality earnings.

Growing Profit Margin: CIPLA's current net profit margins (9%) are lower than last year (9.4%).


Past Earnings Growth Analysis

Earnings Trend: CIPLA's earnings have grown by 3.4% per year over the past 5 years.

Accelerating Growth: CIPLA's earnings growth over the past year (1.2%) is below its 5-year average (3.4% per year).

Earnings vs Industry: CIPLA earnings growth over the past year (1.2%) underperformed the Pharmaceuticals industry 22%.


Return on Equity

High ROE: CIPLA's Return on Equity (9.3%) is considered low.


Next Steps

Financial Health

How is Cipla's financial position?


Financial Position Analysis

Short Term Liabilities: CIPLA's short term assets (₹117.1B) exceed its short term liabilities (₹43.9B).

Long Term Liabilities: CIPLA's short term assets (₹117.1B) exceed its long term liabilities (₹32.1B).


Debt to Equity History and Analysis

Debt Level: CIPLA's debt to equity ratio (17.5%) is considered satisfactory.

Reducing Debt: CIPLA's debt to equity ratio has increased from 16% to 17.5% over the past 5 years.

Debt Coverage: CIPLA's debt is well covered by operating cash flow (108.9%).

Interest Coverage: CIPLA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Cipla's current dividend yield, its reliability and sustainability?

0.47%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CIPLA's dividend (0.47%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.83%).

High Dividend: CIPLA's dividend (0.47%) is low compared to the top 25% of dividend payers in the Indian market (3.4%).


Stability and Growth of Payments

Stable Dividend: CIPLA's dividends per share have been stable in the past 10 years.

Growing Dividend: CIPLA's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (15.6%), CIPLA's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CIPLA's dividends in 3 years are forecast to be well covered by earnings (16.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Umang Vohra (48yo)

3.75yrs

Tenure

₹150,300,000

Compensation

Mr. Umang Vohra, B.E., M.B.A. has been Global Chief Executive Officer and Managing Director of Cipla Limited since September 1, 2016. Mr. Vohra served as the Global Chief Operating Officer of Cipla Limited ...


CEO Compensation Analysis

Compensation vs Market: Umang's total compensation ($USD2.00M) is above average for companies of similar size in the Indian market ($USD1.21M).

Compensation vs Earnings: Umang's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Umang Vohra
MD, Global CEO & Director3.75yrs₹150.30m0.031% 159.1m
Samina Vaziralli
Executive Vice Chairperson3.75yrs₹64.10m2.22% 11.5b
Kedar Upadhye
Global Chief Financial Officer3.83yrs₹35.53m0.0050% 26.0m
Rajendra Chopra
Compliance Officer & Company Secretary3.33yrs₹14.40mno data
Geena Malhotra
President1.58yrsno data0.0095% 49.1m
Raju Mistry
President & Global Chief People Officer1.17yrsno datano data
Pradeep Bhadauria
President & Chief Scientific Officer0.25yrno datano data
Raghunathan Ananthanarayanan
Global Chief Operating Officer1.83yrsno datano data
Alpesh Dalal
Head of Investor Relationsno datano datano data
Gautam Rohidekar
Chief Legal Officer5.67yrsno datano data

3.3yrs

Average Tenure

45.5yo

Average Age

Experienced Management: CIPLA's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Umang Vohra
MD, Global CEO & Director3.75yrs₹150.30m0.031% 159.1m
Samina Vaziralli
Executive Vice Chairperson3.75yrs₹64.10m2.22% 11.5b
Yusuf Hamied
Non-Executive Chairman7.17yrs₹20.20m20.34% 105.1b
Mustafa Hamied
Non Executive Vice-Chairman6.17yrs₹20.70m4.29% 22.2b
Ashok Sinha
Non-Executive Independent Director6.92yrs₹4.60mno data
Punita Lal
Non-Executive Independent Director5.58yrs₹4.10mno data
Naina Lal Kidwai
Non-Executive Independent Director4.58yrs₹4.30mno data
Adil Zainulbhai
Lead Independent Director2.83yrs₹3.80mno data
S. Radhakrishnan
Non-Executive Non Independent Director9.58yrs₹49.80m0.025% 130.9m
Peter Mugyenyi
Non-Executive Independent Director6.33yrs₹4.30mno data

5.9yrs

Average Tenure

64yo

Average Age

Experienced Board: CIPLA's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CIPLA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cipla Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cipla Limited
  • Ticker: CIPLA
  • Exchange: NSEI
  • Founded: 1935
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹516.961b
  • Shares outstanding: 806.24m
  • Website: https://www.cipla.com

Number of Employees


Location

  • Cipla Limited
  • Cipla House
  • Peninsula Business Park
  • Mumbai
  • Maharashtra
  • 400013
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500087BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 1995
CIPLANSEI (National Stock Exchange of India)YesEquity SharesININRFeb 1995
CIPLABDL (Bourse de Luxembourg)GDR EACH REPR 1 ORD SHS OF INR2 REG'SLUUSDMay 2006

Biography

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides inhalation therapy devices comprising metered-dose inhalers, dry powder inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices. It operates in South East Asia, the Middle East, Latin America, South Africa, Europe, North America, Australia, New Zealand, Russia, and internationally. The company has partnership with CSIR-Indian Institute of Chemical Technology for the development of anti- viral drugs to contain COVID-19. Cipla Limited was founded in 1935 and is based in Mumbai, India. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 13:12
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.